Alpha Tau Medical Ltd.

NASDAQ:DRTS

Biotechnology

Healthcare
$12.01 +0.42%

+$0.04 today

Market cap
$1.11B
Beta
1.20
P/E (TTM)
-15.2
EPS (TTM)
-$0.63
52W Low $2.85High $11.62

Volume 0.64M

Average 0.69M

DRTS Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Alpha Tau Medical Ltd.NASDAQ: DRTS

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$13.31M, compared with -$9.31M a year earlier. Trailing-twelve-month operating income was -$46.29M.

Context

  • Operating income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -17.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.31M-5.6% QoQ
Last fiscal yearDec 2025
-$42.29M-17.3% YoY
LTMMar 2026
-$46.29M-25.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.0%+100.0%+143.0 pp
1 year-17.3%+100.0%+117.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(42.29M) USD
Year-over-year change
-17.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How DRTS compares with its peers on the latest reported figures

  • DRTS's LTM Mar 2026 operating income of -$46.29M is the highest of the 3 companies compared; the peer median is -$97.35M.
  • Its year-over-year change of -25.4% is the 2nd highest of 3, against a peer median of -31.9%.
DRTS Competitors Peer median
Operating Income for DRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$46.29M -25.4%——
AKTSAktis Oncology, Inc.FY2025-$74.68M -43.5%—1149.5%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$120.01M -20.4%—19419.6%
Peer median (excluding DRTS) -$97.35M-31.9%—10284.5%

Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue776K979K1.07M1.1M1.23M
Gross Profit(776K)(979K)(1.07M)(1.1M)(1.23M)
Gross Margin—————
Research & Development11.45M20.89M26.42M27.02M30.83M
Selling, General & Admin2.34M11.25M9.26M7.92M10.22M
Operating Expenses13.79M32.14M34.61M34.94M41.06M
Depreciation & Amortization776K979K1.07M1.1M1.23M
EBITDA(13.22M)(32.74M)(28.03M)(30.3M)(41.06M)
EBITDA Margin—————
Operating Income(13.79M)(32.14M)35.68M(36.04M)(42.29M)
Operating Margin—————
Interest Income211K1.79M4.76M4.28M3.84M
Interest Expense13.27M1.77M39K344K419K
Other Income / Expenses(13.47M)(1.61M)6.54M4.3M(218K)
Income Before Tax(27.26M)(33.74M)(29.14M)(31.74M)(42.51M)
Pre-Tax Margin—————
Income Tax Expense7K20K16K6K121K
Net Income(27.27M)(33.76M)(29.16M)(31.75M)(42.63M)
Net Margin—————
EPS (Basic)(0.67)(0.53)(0.42)(0.45)(0.53)
EPS (Diluted)(0.67)(0.53)(0.42)(0.45)(0.53)
Weighted Avg Shares40.53M63.53M69.38M69.93M80.58M
Weighted Avg Shares (Diluted)40.53M63.53M69.38M69.93M80.58M

Alpha Tau Medical Ltd.

NASDAQ:DRTS

Intrinsic Alpha fair value

Locked

Current Price

$12.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.